Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone

Support Care Cancer. 2012 Jul;20(7):1585-7. doi: 10.1007/s00520-012-1481-0. Epub 2012 May 5.

Authors

A Siniscalchi¹, A Tendas, L Morino, T Dentamaro, A De Bellis, A Perrotti, P de Fabritiis, P Musto, T Caravita

Affiliation

¹ Department of Hematology, S Eugenio Hospital, Tor Vergata University, Piazzale dell'Umanesimo 10, 00100 Rome, Italy. [email protected]

PMID: 22562584
DOI: 10.1007/s00520-012-1481-0

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Dexamethasone / administration & dosage
Drug Eruptions / diagnosis
Drug Eruptions / etiology
Drug Eruptions / pathology
Humans
Lenalidomide
Leukemia, Plasma Cell / drug therapy
Leukemia, Plasma Cell / pathology
Male
Middle Aged
Stevens-Johnson Syndrome / chemically induced*
Stevens-Johnson Syndrome / diagnosis
Stevens-Johnson Syndrome / pathology
Thalidomide / administration & dosage
Thalidomide / adverse effects
Thalidomide / analogs & derivatives*

Substances

Thalidomide
Dexamethasone
Lenalidomide